PaulCurtisHendrieMDPhD
Hematology • Seattle, WAHematologic Oncology, Myeloproliferative Disorder Hematology-Oncology
Hematology at Seattle Cancer Care Alliance
Dr. Hendrie is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
825 Eastlake Ave E
Seattle, WA 98109Phone+1 206-288-1400
Summary
- Dr. Paul Hendrie is a hematologist based in Seattle, WA, with subspecialties in Hematologic Oncology and Myeloproliferative Disorder Hematology-Oncology. He received his medical education from the Indiana University School of Medicine and completed his residency in Internal Medicine there. His fellowship was in Hematology and Medical Oncology at the University of Washington. He has expertise in several areas including amyloidosis, hematologic oncology, myelodysplasia, myelofibrosis, and multiple myeloma. Dr. Hendrie has contributed to multiple publications, some of which have been cited by other professionals.
Education & Training
University of WashingtonFellowship, Hematology and Medical Oncology, 1998 - 2000
Indiana University School of MedicineResidency, Internal Medicine, 1995 - 1998- Indiana University School of MedicineClass of 1995
Certifications & Licensure
WA State Medical License 1998 - 2025
Publications & Presentations
PubMed
- 28 citationsHistiocytic Neoplasms, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.Ronald S. Go, Eric D. Jacobsen, Robert A. Baiocchi, Ilia Buhtoiarov, Erin Butler
Journal of the National Comprehensive Cancer Network. 2021-11-01 - 188 citationsErdheim-Chester disease: consensus recommendations for evaluation, diagnosis, and treatment in the molecular eraGaurav Goyal, Mark L. Heaney, Matthew Collin, Fleur Cohen-Aubart, Augusto Vaglio
Blood. 2020-05-28 - 10 citationsEarly hospital discharge after intensive induction chemotherapy for adults with acute myeloid leukemia or other high-grade myeloid neoplasm.Anna B. Halpern, Nicholas P Howard, Megan Othus, Paul C. Hendrie, Nikita V Baclig
Leukemia. 2020-02-01
Journal Articles
- Phase 1/2 Trial of Cladribine, High-Dose Cytarabine, Mitoxantrone, and G-CSF with Dose-Escalated Mitoxantrone for relapsed/refractory Acute Myeloid Leukemia or Other H...Kelda M Gardner, Vivian G Oehler, Heather A Smith, Anna B Halpern, Paul C Hendrie, Sarah A Buckley, Roland B Walter, Pamela S Becker, Ryan D Cassaday, Asma Anwar, Bart..., Haematologica
Abstracts/Posters
- Comparison of Outcomes after Early Hospital Discharge (EHD) Following Intensive Induction Vs. Post-Remission Chemotherapy for Adults with Acute Myeloid Leukemia (AML) ...Paul C. Hendrie, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Additional Cytotoxic Chemotherapy Is Unlikely to Eliminate Measurable Residual Acute Myeloid Leukemia (AML)Paul C. Hendrie, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Mini- Vs. Regular-Dose CLAG-M (Cladribine, Cytarabine, G-CSF, and Mitoxantrone) in Medically Less Fit Adults with Newly-Diagnosed Acute Myeloid Leukemia (AML) and Othe...Paul C. Hendrie, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Join now to see all
Professional Memberships
- Member
- Histiocyte SocietyMember
External Links
- SCCAhttp://www.seatttlecca.org
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
